Cargando…

The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice

BACKGROUND & AIMS: In recent years, nonalcoholic steatohepatitis (NASH) has become a considerable healthcare burden worldwide. Pathogenesis of NASH is associated with type 2 diabetes mellitus (T2DM) and insulin resistance. However, a specific drug to treat NASH is lacking. We investigated the ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Honda, Yasushi, Imajo, Kento, Kato, Takayuki, Kessoku, Takaomi, Ogawa, Yuji, Tomeno, Wataru, Kato, Shingo, Mawatari, Hironori, Fujita, Koji, Yoneda, Masato, Saito, Satoru, Nakajima, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701474/ https://www.ncbi.nlm.nih.gov/pubmed/26731267 http://dx.doi.org/10.1371/journal.pone.0146337

Ejemplares similares

Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis
por: Kessoku, Takaomi, et al.
Publicado: (2016)

Soluble CD14 Levels Reflect Liver Inflammation in Patients with Nonalcoholic Steatohepatitis
por: Ogawa, Yuji, et al.
Publicado: (2013)

Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis
por: Honda, Yasushi, et al.
Publicado: (2017)

Identification of differentially methylated region (DMR) networks associated with progression of nonalcoholic fatty liver disease
por: Hotta, Kikuko, et al.
Publicado: (2018)

Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin
por: Ogawa, Yuji, et al.
Publicado: (2018)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

LDL-Migration Index (LDL-MI), an Indicator of Small Dense Low-Density Lipoprotein (sdLDL), Is Higher in Non-Alcoholic Steatohepatitis than in Non-Alcoholic Fatty Liver: A Multicenter Cross-Sectional Study
por: Imajo, Kento, et al.
Publicado: (2014)

Involvement of Periodontal Disease in the Pathogenesis and Exacerbation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: A Review
por: Kobayashi, Takashi, et al.
Publicado: (2023)

Two differentially methylated region networks in nonalcoholic fatty liver disease, viral hepatitis, and hepatocellular carcinoma
por: Kurokawa, Suguru, et al.
Publicado: (2022)

Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan
por: Yoneda, Masato, et al.
Publicado: (2021)

Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study
por: Honda, Yasushi, et al.
Publicado: (2017)

Coronary Artery Disease is More Severe in Patients with Non-Alcoholic Steatohepatitis than Fatty Liver
por: Niikura, Toshihiro, et al.
Publicado: (2020)

Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs
por: Tomeno, Wataru, et al.
Publicado: (2020)

Plasma Pentraxin3 is a Novel Marker for Nonalcoholic Steatohepatitis (NASH)
por: Yoneda, Masato, et al.
Publicado: (2008)

The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target
por: Kessoku, Takaomi, et al.
Publicado: (2021)

A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costs
por: Kobayashi, Takashi, et al.
Publicado: (2022)

Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model
por: Nozaki, Yuichi, et al.
Publicado: (2015)

Unfolded protein response pathways regulate Hepatitis C virus replication via modulation of autophagy
por: Shinohara, Yoshiyasu, et al.
Publicado: (2013)

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
por: Takahashi, Hirokazu, et al.
Publicado: (2021)

Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort
por: Imajo, Kento, et al.
Publicado: (2021)

Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial
por: Yoneda, Masato, et al.
Publicado: (2022)

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
por: Sumida, Yoshio, et al.
Publicado: (2020)

SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model
por: Tahara, Atsuo, et al.
Publicado: (2019)

Peroxisome Proliferator-Activated Receptor Gamma Exacerbates Concanavalin A-Induced Liver Injury via Suppressing the Translocation of NF-κB into the Nucleus
por: Ogawa, Yuji, et al.
Publicado: (2012)

Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD
por: Nogami, Asako, et al.
Publicado: (2022)

Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease
por: Kawamura, Nobuyoshi, et al.
Publicado: (2022)

Gastroesophageal varices evaluation using spleen‐dedicated stiffness measurement by vibration‐controlled transient elastography
por: Nagai, Koki, et al.
Publicado: (2021)

Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study
por: Ozaki, Anna, et al.
Publicado: (2020)

Association of Serum and Fecal Bile Acid Patterns With Liver Fibrosis in Biopsy-Proven Nonalcoholic Fatty Liver Disease: An Observational Study
por: Kasai, Yuki, et al.
Publicado: (2022)

Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model
por: Morishita, Asahiro, et al.
Publicado: (2022)

Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
por: Honda, Yasushi, et al.
Publicado: (2020)

Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease
por: Kessoku, Takaomi, et al.
Publicado: (2020)

Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study)
por: Ozaki, Anna, et al.
Publicado: (2019)

Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
por: Yoneda, Masato, et al.
Publicado: (2021)

Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods
por: Yoneda, Masato, et al.
Publicado: (2017)

Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study
por: Iwaki, Michihiro, et al.
Publicado: (2022)

Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease
por: Iwaki, Michihiro, et al.
Publicado: (2023)

Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution
por: Nozaki, Yuichi, et al.
Publicado: (2015)

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
por: Nogami, Asako, et al.
Publicado: (2023)

Endotoxins and Non-Alcoholic Fatty Liver Disease
por: Kessoku, Takaomi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_91ribe9nq3s8t33phsm2mjm5q3